ABX 10241Alternative Names: ABX-PTH; ABX10241; Human anti-parathyroid hormone monoclonal antibody; human anti-PTH monoclonal antibody
Latest Information Update: 10 Sep 2008
At a glance
- Originator Abgenix
- Class Monoclonal antibodies
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hyperparathyroidism
Most Recent Events
- 03 Apr 2006 Abgenix has been acquired and merged into Amgen
- 18 May 2005 ABX-10241 is available for ex-US licensing (http://www.abgenix.com)
- 11 May 2005 Enrolment into a phase I study is ongoing